XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

Xenon Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference

BURNABY, British Columbia, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, December 4, 2019 at 3:00 pm Eastern Time.

A live audio webcast will be available on the investors section of Xenon's website at and will be posted for replay following the event.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit .

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:

Jodi Regts

Xenon Pharmaceuticals Inc.

Phone: 604.484.3353

Email:

EN
03/12/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

 PRESS RELEASE

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Bus...

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain Pro forma cash of $716 million including recent ATM sales extends cash runway into second half of 2027Xenon...

Wedbush Research
  • Wedbush Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch